On April 20, following the completion of a Pre-C round strategic financing worth tens of millions of RMB last month, medical device company Weimai Medical announced that it has secured another round of strategic investment from Shouke Medical Valley, a professional incubation and technology commercialization platform built on the resources of Capital Medical University, its affiliated hospitals, and clinical teaching institutions.
Weimai Medical stated that the newly raised funds will be primarily used to deepen clinical research, improve its evidence-based medicine system, and strengthen its capabilities in integrating medical and engineering technologies. This also marks another substantive step forward in the company’s pursuit of medical specialization, with its systematic capabilities and platform strength expected to see a comprehensive upgrade.
According to public information, Weimai Medical was founded in 2021 and is a high-tech enterprise focused on the R&D of medical devices. Its flagship medical aesthetics product, the YOUMAGIC high-energy monopolar radiofrequency skin treatment device, promotes a “more powerful, more comfortable, and more effective” anti-aging experience. It is the first radiofrequency device in China to have obtained both a Class III medical device certification from the NMPA and certification from the FDA.
“We believe that with the support of Shouke Medical Valley’s top-tier medical resources and capital, the company will further strengthen its medical-engineering integration layout, focus on real clinical needs, enhance innovation and commercialization efficiency in medical device technologies, and consolidate its professional advantages and leading position in the field of energy-based medicine,” Weimai Medical said.
It is worth noting that since its establishment, Weimai Medical has experienced rapid growth and has completed a total of 13 funding rounds. Among its investors are well-known Chinese beauty companies and prominent investment institutions, including Proya, Botanee, and Ziniu Fund. Notably, Botanee invested in the company twice, in 2023 and 2024.
